Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | ($32.3M) | ($43.5M) | ($39.5M) | ($93.2M) | ($27.8M) | ($48.1M) | ($44.1M) | ($54.8M) | ($129.5M) | ($92.9M) | ($405.0M) | ($296.0M) | ($424.6M) | ($500.1M) | ($814.7M) | ($939.4M) | ($828.4M) | ($708.7M) | ($785.1M) | ($282.2M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month Operating Income is ($188.1M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Alnylam Pharmaceuticals, Inc.'s Operating Income growth was (46.9%). The average annual Operating Income growth rates for Alnylam Pharmaceuticals, Inc. have been (38.4%) over the past three years, (26.2%) over the past five years.
Over the last year, Alnylam Pharmaceuticals, Inc.'s Operating Income growth was (46.9%), which is lower than industry growth of (0.1%). It indicates that Alnylam Pharmaceuticals, Inc.'s Operating Income growth is Bad.